Reproductive Medicine & Human Fertility

The primary research record in Reproductive Medicine & Human Fertility is stratified by study design so that meta-analyses and replicated randomised controlled trials (T1–T2) carry greater epistemic weight than observational cohorts (T3–T4) or preclinical laboratory work (T5). Leading graded findings establish the core empirical baseline: [T1] In couples with high sperm DNA fragmentation, testicular sperm (TESA/TESE) has 3- to 4-fold lower DNA damage than ejaculated sperm and increases ICSI live birth rates (RR 1.75) while cutting miscarriage rates. [25] [T2] Nightly prophylaxis with 150 mg low-dose aspirin initiated at 11–14 weeks gestation reduces the incidence of preterm pre-eclampsia by 62% (OR 0.38). [13][24]

Further clinical and mechanistic stratification across the literature demonstrates: [T3] Double ovarian stimulation in the follicular and luteal phases of the same menstrual cycle (DuoStim) doubles the harvest of mature autologous oocytes and euploid blastocysts within 28 days. [22] [T3] BackgroundSemen quality is taken as a surrogate measure of male fecundity in clinical andrology, male fertility, reproductive toxicology, epidemiology and pregnancy risk assessments. [29]

When evaluated as a quantitative decision and mechanism ledger, the best-supported interventions and frameworks in Reproductive Medicine & Human Fertility are: DuoStim (Shanghai Double Stimulation Protocol) (Supported — Doubles mature oocyte and euploid blastocyst yield within 30 days; luteal oocytes match or exceed follicular quality; landmark evidence: Multicenter prospective cohorts & meta-analyses (Vaiarelli et al. 2020; Ubaldi et al. 2016): Essential time-saving protocol when maternal age is 40+, preventing cycle drop-out and capturing asynchronous follicle waves.); Growth Hormone (Omnitrope / Somatropin) Co-Stimulation (Targeted — Increases retrieved mature oocytes (MD +1.4) and cleavage/blastocyst formation; modest live birth gain in poor responders; landmark evidence: Cochrane & systematic reviews of RCTs in poor ovarian responders (Cozzolino et al. 2020; Duffy et al.): Most effective when started 4–6 weeks before stimulation or during micro-flare protocols in diminished ovarian reserve.); In Vitro Activation (IVA) & Hippo Signaling Disruption (Targeted — Awakens silent residual primordial follicles into preantral/antral stages capable of responding to FSH stimulation, yielding autologous live births; landmark evidence: Kawamura, Cheng, Hsueh et al., PNAS 2013 & multicenter clinical cohorts in Japan/Spain: Designed for women with severe diminished ovarian reserve or early perimenopause who still retain dormant primordial follicles.).

By contrast, interventions and hypotheses that remain experimental, subgroup-restricted, or unsupported by randomised endpoints include: Maternal Spindle Transfer (MST) / Pronuclear Transfer (PNT) (Trial only — 6 healthy live births from 25 couples with 3–11 prior failed IVF cycles and complete embryonic arrest; >99% donor mtDNA stability; Preserves 100% of maternal and paternal nuclear genes (~20,000+ genes) while replacing aged mitochondrial batteries via donor cytoplasm.); Engineered Ovarian Support Cell IVM (Gameto Fertilo) (Trial only — Increases MII maturation (~70% vs ~45% standard IVM) and euploid blastocyst conversion without high-dose gonadotropin toxicity; Recreates a youthful follicular signaling niche in the dish using engineered support tissue while keeping the egg 100% genetically autologous.); Low-Dose Rapamycin (mTORC1 Inhibition) (Trial only — Extends ovarian lifespan by ~30% in mammals; human pilot trial reports slowed follicular loss and preserved anti-Müllerian hormone; First human geroscience clinical trial directly targeting the molecular clock of ovarian aging.).

Within the Tree of Knowledge, this field branches into 16 specialised sub-disciplines: Advanced Maternal Age & Pregnancy After 40 (Maternal cardiovascular and metabolic adaptation, hypertensive disorders of pregnancy, gestational diabetes, placental biology, and perinatal outcomes in pregnancy after age 40); Andrology & Male Factor Infertility (Spermatogenesis, sperm chromatin and DNA integrity, paternal age effects after 40 across the population, varicocele, and clinical interventions); Assisted Reproductive Technology & Gamete Donation (In vitro fertilisation, intracytoplasmic sperm injection, embryo selection, third-party reproduction, outcomes, and international regulatory frameworks); Assisted reproduction (Research IVF and new potential venues such as out of womb embryology and egg donor DNA replacement, etc... what else is there in the edge?); Clinical Nutrition and Assisted Reproductive Technology Outcomes (Evaluation of pre-conception weight management and dietary interventions on live birth rates during in vitro fertilization cycles for individuals aged 40 and over).

Chronologically, the field evolved through key inflection points: in 1978, Human Fertility: The Basic Components. (In this innovative and comprehensive work, expanded by one-third for the English-language edition, Henri Leridon integrates biology and demography to investigate human fertility, both natural and controlled); in 2010, World Health Organization reference values for human semen characteristics. (BackgroundSemen quality is taken as a surrogate measure of male fecundity in clinical andrology, male fertility, reproductive toxicology, epidemiology and pregnancy risk assessments); in 2013, In Vitro Activation (IVA) via Hippo Pathway Disruption (Kawamura and Hsueh (Stanford / St. Marianna) demonstrate that ovarian cortical fragmentation awakens dormant primordial follicles, leading to human live births); in 2017, ASPRE Trial Establishes 150 mg Aspirin Pre-eclampsia Prophylaxis (NEJM multicenter RCT proves 150 mg nightly aspirin starting at 12 weeks cuts preterm pre-eclampsia by 62%).

Active scientific debates and unresolved methodological tensions centre on: PGT-A Trophectoderm Biopsy vs. Fresh Day 3 Cleavage Transfer in Women Aged 40+: While PGT-A prevents transferring lethal aneuploid blastocysts, critics (e.g., Gleicher et al.) demonstrate that in women with ≤3 oocytes, extended culture to Day 5 and laser biopsy cause high embryo loss and discard self-correcting mosaic embryos that could produce healthy live births if transferred on Day 3. (contested) Maternal Spindle Transfer (MST) for Age-Related Infertility vs. Cytoplasmic vs. Chromosomal Aging: MST replaces aged oocyte mitochondria with young donor cytoplasm while preserving 100% maternal nuclear chromosomes. Skeptics note that if cohesin loss has already occurred in Prophase I prior to Metaphase II spindle extraction, cytoplasmic rescue improves blastocyst development from arrest to euploid transfer only in the subset of oocytes whose chromosomes segregated intact. (debated) PGT-A Trophectoderm Biopsy vs. Fresh Day 3 Cleavage Transfer in Women Aged 40+: While PGT-A prevents transferring lethal aneuploid blastocysts, critics (e.g., Gleicher et al.) demonstrate that in women with ≤3 oocytes, extended culture to Day 5 and laser biopsy cause high embryo loss and discard self-correcting mosaic embryos that could produce healthy live births if transferred on Day 3. (contested)

Active research groups, trials, and regulatory benchmarks tracked in this space include Institute of Life – IASO Hospital (Athens) (Greece) — Clinical center that conducted the landmark Maternal Spindle Transfer (MST) trial with Embryotools, achieving live births with 100% parental nuclear DNA; Conception Bio (In Vitro Gametogenesis) (United States) — San Francisco biotechnology group developing human In Vitro Gametogenesis (reprogramming adult somatic cells into iPSCs, PGCLCs, and functional human oocytes); Gameto Inc. (Fertilo Engineered IVM) (United States) — Biotechnology company using human iPSC-derived ovarian support cells (Fertilo) to mature immature autologous eggs outside the body (Phase 3 NCT06858111); Embryotools (Parc Científic de Barcelona) (Spain) — Translational embryology research group led by Dr. Nuno Costa-Borges and Dr. Gloria Calderón pioneering Maternal Spindle Transfer micromanipulation.

Methodological priorities and open empirical questions queued for the next research sweep across Reproductive Medicine & Human Fertility focus on resolving subgroup effect sizes, causal mechanisms, and long-term outcomes:

• Long-term longitudinal follow-up and expansion of Maternal Spindle Transfer (MST) trials specifically stratified for women aged 40–45 with autologous oocytes
• Human randomized controlled trial dose-response data for oral spermidine and nicotinamide mononucleotide (NMN) on blastocyst euploidy rates
• Completion of human meiotic chromosome crossover and synapsis in vitro for iPSC-derived In Vitro Gametogenesis (IVG)
• Large-scale multicenter RCT comparing fresh Day 3 cleavage transfer versus PGT-A blastocyst banking in women over 40 with ≤3 oocytes per retrieval
• Large-scale multicentre randomised controlled trials with standardised live-birth and long-term offspring follow-up in Human fertility.
• Age- and subgroup-stratified biomarker validation across diverse human populations.